Using a proprietary model of testing on genetically-modified pigs pioneered at the University of Illinois, Sus Clinicals leverages the inherent advantages of a patent-pending large animal testing methodology combined with novel clinical approaches to reduce false positives, model the interactions of multiple diseases, and accelerate progress toward human trials for the most promising therapies. As such, Sus Clinicals enables “fast cycle learning” to save clients significant time and money against a broad range of cancer therapies that can save lives and deliver commercial success.
Ethics and Governance
Sus Clinicals always strives to adhere to the highest standards of ethical behavior in all we do. We and our research partners comply with all applicable laws and regulations, including standards for the use of biomedical research animals. These include best practices as set forth by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) and the American Association for Laboratory Animal Science (AALAS). We conduct our research with robust team training, comprehensive quality assurance and integrated data management practices. We are also committed to transparency, including disclosing any conflicts of interest that may arise in the course of our work. As part of this, we ensure compliance with requirements under any government-funded or other sponsored research, which includes having a clearly defined Financial Conflict of Interest in Research (FCOIR) policy (Click here to view PDF).